GMAB ▲ +3.5% - Genmab A/S
$GMAB Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
26-OCT-2026 07:03 AM ET
Share this post
More filings for $GMAB
GMAB ▼ -3.6% - Genmab A/SNov 5, 2026GMAB ▲ +0.8% - Genmab A/SNov 4, 2026GMAB ▲ +34.1% - Genmab A/SOct 28, 2026GMAB ▲ +25.5% - Genmab A/SOct 28, 2026GMAB ▲ +19.6% - Genmab A/SOct 28, 2026GMAB ▲ +16.1% - Genmab A/SOct 28, 2026
View full $GMAB filing history →💬 Comments
Loading comments…
Leave a comment